Anika Graham Number from 2010 to 2026

ANIK Stock  USD 10.21  0.15  1.49%   
Anika Therapeutics Graham Number yearly trend continues to be quite stable with very little volatility. Graham Number may rise above 10.71 this year. From the period between 2010 and 2026, Anika Therapeutics, Graham Number regression line of its data series had standard deviation of  7.97 and standard deviation of  7.97. View All Fundamentals
 
Graham Number  
First Reported
2010-12-31
Previous Quarter
10.21
Current Value
10.71
Quarterly Volatility
7.9721528
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.8 M, Interest Expense of 2.8 M or Selling General Administrative of 67.1 M, as well as many indicators such as Price To Sales Ratio of 3.32, Dividend Yield of 0.0 or PTB Ratio of 1.71. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Anika Stock
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
Historical Graham Number data for Anika Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Anika Therapeutics represents a compelling investment opportunity.

Latest Anika Therapeutics' Graham Number Growth Pattern

Below is the plot of the Graham Number of Anika Therapeutics over the last few years. It is Anika Therapeutics' Graham Number historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anika Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Graham Number10 Years Trend
Pretty Stable
   Graham Number   
       Timeline  

Anika Graham Number Regression Statistics

Arithmetic Mean17.04
Geometric Mean15.45
Coefficient Of Variation46.77
Mean Deviation7.16
Median11.35
Standard Deviation7.97
Sample Variance63.56
Range20.9769
R-Value(0.25)
Mean Square Error63.46
R-Squared0.06
Significance0.33
Slope(0.40)
Total Sum of Squares1,017

Anika Graham Number History

2026 10.71
2025 10.21
2020 11.35
2019 29.75
2018 23.07
2017 29.8
2016 27.51

About Anika Therapeutics Financial Statements

Anika Therapeutics investors utilize fundamental indicators, such as Graham Number, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Graham Number 10.21  10.71 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anika Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.51)
Earnings Share
(0.99)
Revenue Per Share
7.826
Quarterly Revenue Growth
(0.06)
Return On Assets
(0.04)
Anika Therapeutics's market price often diverges from its book value, the accounting figure shown on Anika's balance sheet. Smart investors calculate Anika Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Anika Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Anika Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anika Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.